Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Trial of Lurbinectedin Plus Doxorubicin in Leiomyosarcoma

NCT05099666 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT05099666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05099666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Trial of Lurbinectedin Plus Doxorubicin in Leiomyosarcoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
February 4, 2022
Completion date
July 31, 2028
Enrollment
62 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced leiomyosarcoma, advanced soft-tissue sarcoma, leiomyosarcoma metastatic, metastatic soft-tissue sarcoma